Novartis India has acquired the 'Minipress' hypertension brand from Pfizer for ₹1,250 crore, expanding its cardiovascular portfolio as Pfizer exits the category. While the move helps secure an established product line, the purchase price represents a significant premium over the brand's annual sales. Shares of Novartis India rose nearly 4% following the announcement.
Novartis India Ltd has finalized an agreement to purchase the 'Minipress' and 'Minipres' trademarks along with related intellectual property from US-based Pfizer Inc. and its subsidiary, Pfizer Products Inc. The transaction, valued at ₹1,250 crore, was signed and closed in a single session. Following the news, the company’s stock saw positive movement, rising approximately 4% in trading.
Expanding the Hypertension Portfolio
The acquisition centers on Minipress XL, a drug commonly prescribed for hypertension and urinary symptoms related to benign prostatic hyperplasia. According to market data through July 2026, the brand generates roughly ₹228.6 crore in annual revenue. The product has maintained a steady commercial presence with a compound annual growth rate of 6.3 percent over the last four years. By bringing this brand under its umbrella, Novartis India intends to strengthen its position in the domestic cardiovascular treatment market.
Strategic Exit by Pfizer
This transaction marks the end of Pfizer’s involvement with the Minipress brand in India. Pfizer has confirmed that it will immediately cease the marketing, distribution, and sale of the product. This decision aligns with a broader corporate strategy by the global parent company, Pfizer Inc., to stop manufacturing this specific product line. As a result of this global exit, Pfizer Ltd is set to receive a lump-sum payment of approximately ₹131.38 crore from its parent entity.
Valuation and Market Risks
While the acquisition brings an established brand into the Novartis fold, investors may note the valuation. At ₹1,250 crore, the price paid is roughly 5.5 times the brand's annual revenue of ₹228.6 crore. This indicates that Novartis is paying a significant premium for the brand’s long-term equity and market position rather than relying on current profitability alone.
Furthermore, the hypertension treatment sector is highly competitive. Minipress XL relies on the active ingredient prazosin, which is available from various other manufacturers, including generic players like Alembic Pharmaceuticals. Success for Novartis will depend on its ability to maintain brand loyalty during this transition and effectively manage supply chain continuity. Investors may track the company's upcoming updates regarding the integration of this new asset and any changes in the product's market share in the coming quarters.